Profund Advisors LLC Makes New $238,000 Investment in POINT Biopharma Global Inc. (NASDAQ:PNT)

Profund Advisors LLC purchased a new position in shares of POINT Biopharma Global Inc. (NASDAQ:PNTFree Report) during the 1st quarter, Holdings Channel.com reports. The institutional investor purchased 32,709 shares of the company’s stock, valued at approximately $238,000.

Several other institutional investors have also modified their holdings of the company. American Century Companies Inc. boosted its stake in shares of POINT Biopharma Global by 73.2% during the 1st quarter. American Century Companies Inc. now owns 22,344 shares of the company’s stock worth $155,000 after acquiring an additional 9,446 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of POINT Biopharma Global by 12.2% during the 1st quarter. Rhumbline Advisers now owns 113,324 shares of the company’s stock worth $824,000 after acquiring an additional 12,344 shares in the last quarter. Citigroup Inc. boosted its stake in shares of POINT Biopharma Global by 4.6% during the 1st quarter. Citigroup Inc. now owns 137,279 shares of the company’s stock worth $998,000 after acquiring an additional 6,003 shares in the last quarter. Pier Capital LLC purchased a new stake in shares of POINT Biopharma Global during the 1st quarter worth approximately $6,272,000. Finally, Credit Suisse AG lifted its stake in POINT Biopharma Global by 11.7% in the 1st quarter. Credit Suisse AG now owns 59,701 shares of the company’s stock valued at $434,000 after buying an additional 6,261 shares in the last quarter. Hedge funds and other institutional investors own 59.53% of the company’s stock.

POINT Biopharma Global Price Performance

PNT stock opened at $7.76 on Friday. POINT Biopharma Global Inc. has a 52-week low of $5.59 and a 52-week high of $11.13. The stock’s fifty day simple moving average is $8.71 and its 200-day simple moving average is $8.48. The company has a quick ratio of 10.51, a current ratio of 10.51 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $820.78 million, a price-to-earnings ratio of 8.92 and a beta of 0.13.

POINT Biopharma Global (NASDAQ:PNTGet Free Report) last issued its earnings results on Monday, August 14th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.05. The firm had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $8.50 million. Equities research analysts expect that POINT Biopharma Global Inc. will post -1 EPS for the current year.

Analysts Set New Price Targets

PNT has been the topic of a number of analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $14.00 target price (up previously from $12.00) on shares of POINT Biopharma Global in a report on Thursday, July 20th. Raymond James set a $13.00 target price on POINT Biopharma Global and gave the company an “outperform” rating in a report on Monday, August 28th. Finally, Piper Sandler increased their target price on POINT Biopharma Global from $14.00 to $16.00 in a report on Wednesday, June 21st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, POINT Biopharma Global presently has an average rating of “Buy” and a consensus target price of $16.00.

View Our Latest Stock Analysis on PNT

About POINT Biopharma Global

(Free Report)

POINT Biopharma Global Inc, a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.

Further Reading

Want to see what other hedge funds are holding PNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for POINT Biopharma Global Inc. (NASDAQ:PNTFree Report).

Institutional Ownership by Quarter for POINT Biopharma Global (NASDAQ:PNT)

Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.